Sorbitol plus chemo and immunotherapy for advanced gastric cancer
Part of Cancer, Digestive system clinical trials.
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old.
- You have been diagnosed with stomach or gastroesophageal junction cancer that is HER2-negative and has not been treated yet.
- Your cancer is locally advanced (stage cT3-4N+M0) and is a type called adenocarcinoma.
- You are in good physical condition (ECOG score 0 or 1).
- Your major organs (blood, liver, kidneys) are working well based on blood tests.
- You are not pregnant and agree to use birth control during and for 8 weeks after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This phase 3 study compares two versions of a first-time treatment for HER2-negative advanced stomach or gastroesophageal cancer, both including immunotherapy (sintilimab). It looks for a safer or more effective way to slow cancer growth or improve outcomes.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of an immunotherapy drug (tislelizumab) and chemotherapy after surgery to prevent stomach cancer from coming back in older patients. It may be a good option for people who have had their cancer completely removed and are in good overall health.
This trial tests whether adding a short course of radiation to a combination of immunotherapy (PD-1 inhibitor) and chemotherapy (SOX) before surgery helps treat advanced stomach or GEJ cancer. It aims to see if the extra radiation makes the treatment more effective.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.